OXCARBAZEPINE | A217659 | AJANTA PHARMA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited 10 patentsANDA 217659oxcarbazepine | D. Del. | 2022-10-28 | Terminated 2024-01-18 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$9.38
per ea
Lowest NADAC/Unit
$3.41
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 27241023901OXCARBAZEPINE ER 600 MG TABLET | $9.38 | EA | Generic | — | 2026-10-21 |
| 27241023801OXCARBAZEPINE ER 300 MG TABLET | $4.91 | EA | Generic | — | 2026-10-21 |
| 27241023701OXCARBAZEPINE ER 150 MG TABLET | $3.41 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.